ESC Guidelines Updated for Managing CVD in Diabetes
Guidelines address lifestyle recommendations, individualized BP targets, SGLT2 inhibitor, GLP1-RA tx
THURSDAY, Sept. 5, 2019 (HealthDay News) -- In updated guidelines developed by the European Society of Cardiology, in collaboration with the European Association for the Study of Diabetes, recommendations are presented for the prevention and management of cardiovascular disease (CVD) in diabetes. The guidelines were published online Aug. 31 in the European Heart Journal to coincide with the European Society of Cardiology Congress 2019, held from Aug. 31 to Sept. 4 in Paris.
Francesco Cosentino, M.D., Ph.D., from the Karolinska Institute in Stockholm, and colleagues developed guidelines on prevention and management of CVD in individuals with and at risk for developing diabetes mellitus.
The authors note that individuals without CVD with prediabetes are not necessarily at elevated CV risk but should be classified for risk in the same way as the general population. In terms of lifestyle recommendations, moderate alcohol intake should not be promoted to prevent CVD. Patients with prediabetes or diabetes should be encouraged to quit smoking, reduce calorie intake to lower excessive body weight, adopt a Mediterranean diet supplemented with olive oil and/or nuts, and engage in moderate-to-vigorous physical activity for at least 150 minutes per week, unless contraindicated. Detailed recommendations are provided for individualized blood pressure targets, including self-monitoring of blood pressure. For patients with CVD or at high CV risk, sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide receptor agonists are recommended as glucose-lowering treatment for type 2 diabetes.
"The effects of advancing age and comorbidities indicate the need to manage risk in an individualized manner, empowering the patient to take a major role in the management of his or her condition," the authors write.